TY  - JOUR
AU  - Katz, Deborah A
AU  - Morris, Joan D
AU  - Chu, Michael P
AU  - David, Kevin A
AU  - Thieblemont, Catherine
AU  - Morley, Nicholas J
AU  - Khan, Sharif S
AU  - Viardot, Andreas
AU  - Martín García-Sancho, Alejandro
AU  - Rodríguez-García, Guillermo
AU  - Bastos-Oreiro, Mariana
AU  - Lee, Seung Tae
AU  - Kormany, William
AU  - Chen, Yuqi
AU  - Wong, Hansen L
AU  - Anderson, Abraham A
AU  - Katlinskaya, Yuliya
AU  - Avilion, Ariel A
AU  - Dai, Tian
AU  - González-Barca, Eva
PY  - 2022
DO  - 10.1080/10428194.2022.2064981
UR  - http://hdl.handle.net/10668/19676
T2  - Leukemia & lymphoma
AB  - This open-label, multicenter, single-arm, phase 2 study assessed the safety and efficacy of blinatumomab consolidation therapy in adult patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL; International Prognostic Index 3-5...
LA  - en
KW  - Relapsed/refractory
KW  - blinatumomab
KW  - high-risk DLBCL
KW  - Adult
KW  - Antibodies, Bispecific
KW  - Humans
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - Proto-Oncogene Proteins c-bcl-2
KW  - Remission Induction
TI  - Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.
TY  - research article
VL  - 63
ER  -